Published in Mental Health Law Weekly, July 15th, 2006
The study showed the number of patients receiving a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) decreased 11.9%.
The FDA issued the black-box warning after a safety review indicated an increased risk of suicide among pediatric antidepressant users. In order to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.